Daiichi Gets Rare Patent Board Rehearing in Drug Dispute (1)

Daiichi Sankyo Co. and AstraZeneca Pharmaceuticals LP were granted a rare administrative patent tribunal rehearing after the board rejected their original challenge to a patent they were accused of infringing.

The Patent Trial and Appeal Board initially refused to review Seagen Inc.'s U.S. Patent No. 10,808,039 because of potential conflicting results from the board and the outcome of the parties’ trial at the U.S. District Court for the Eastern District of Texas. The PTAB said it can grant a rehearing on some Seagen claims on the patent because the company dropped them from the district court litigation.

The board found ...